Blood Test for P-Tau217 Protein May Predict Dementia Risk Years in Advance
New biomarker could identify dementia risk decades before symptoms appear, enabling earlier intervention strategies.
20 articles
New biomarker could identify dementia risk decades before symptoms appear, enabling earlier intervention strategies.
Pfizer's landmark trial examines whether tafamidis can safely treat transthyretin amyloid cardiomyopathy, a progressive and often fatal heart condition.
A pathological study ties common Lp(a) risk gene variants to specific coronary thrombosis morphologies in sudden cardiac death victims.
A proteomics screen of 2,920 plasma proteins identifies a 17-protein score that lifts heart failure prediction accuracy to 0.833 C-index in type 2 diabetes patients.
In 2,040 coronary angiography patients, OxPL-apoB predicted MI-free survival but showed no link to platelet reactivity, implicating Lp(a) as the key mediator.
New research reveals how eliminating urokinase plasminogen activator can temporarily protect against diet-induced weight gain and metabolic dysfunction.
A 330-patient multicenter RCT tests whether thymosin ฮฑ1 can curb immune dysregulation and organ dysfunction after acute type A aortic dissection repair.
A feedforward ANGPT-TIE2 signaling loop amplifies PIK3CA-driven venous malformations, pointing to TIE2 inhibition as a more effective therapy than mTOR blockade.
Large UK study reveals elevated Lp(a) levels raise venous thromboembolism risk by 32% in premenopausal women but not in men or postmenopausal women.
A mass spectrometry apolipoprotein panel predicts cardiovascular events and identifies who gains the most from PCSK9 inhibitor therapy.
Meta-analysis of 19,822 people reveals elevated Lp(a) accelerates coronary plaque progression and creates rupture-prone plaques.
New research reveals how GRK2 protein clumping damages brain cells and identifies potential therapeutic targets to slow cognitive decline.
Elevated oxidized phospholipids independently predict major cardiac events after ACS, and alirocumab abolishes that risk signal.
Amgen's siRNA therapy olpasiran targets lipoprotein(a), a stubborn cardiovascular risk factor with no approved treatments.
New ultra-sensitive cardiac troponin T assay promises earlier, more accurate detection of heart muscle damage for better prevention.
New imaging reveals calcified plaques contain active lipid deposits that persist even with very low LDL cholesterol levels below 55 mg/dL.
New research reveals how elevated Lp(a) levels interact with hormonal changes to significantly increase venous thromboembolism risk.
A new PET imaging metric identifies patients with normal scans who still face 41% higher cardiovascular event risk.
CTI index combining inflammation and insulin resistance shows 111% higher death risk in 5,847 Chinese adults.
New CT scan technology can spot dangerous fat around arteries that predicts heart attacks better than traditional methods.